AU2002233560B2 - Vaccine - Google Patents

Vaccine Download PDF

Info

Publication number
AU2002233560B2
AU2002233560B2 AU2002233560A AU2002233560A AU2002233560B2 AU 2002233560 B2 AU2002233560 B2 AU 2002233560B2 AU 2002233560 A AU2002233560 A AU 2002233560A AU 2002233560 A AU2002233560 A AU 2002233560A AU 2002233560 B2 AU2002233560 B2 AU 2002233560B2
Authority
AU
Australia
Prior art keywords
protein
human
sequence
mouse
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002233560A
Other languages
English (en)
Other versions
AU2002233560A1 (en
Inventor
Claire Ashman
James Scott Crowe
Jonathan Henry Ellis
Alan Peter Lewis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2002233560A1 publication Critical patent/AU2002233560A1/en
Application granted granted Critical
Publication of AU2002233560B2 publication Critical patent/AU2002233560B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2002233560A 2001-03-03 2002-03-01 Vaccine Ceased AU2002233560B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0105360.2 2001-03-03
GBGB0105360.2A GB0105360D0 (en) 2001-03-03 2001-03-03 Chimaeric immunogens
PCT/GB2002/000900 WO2002070711A1 (en) 2001-03-03 2002-03-01 Vaccine

Publications (2)

Publication Number Publication Date
AU2002233560A1 AU2002233560A1 (en) 2003-03-13
AU2002233560B2 true AU2002233560B2 (en) 2006-09-07

Family

ID=9909970

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002233560A Ceased AU2002233560B2 (en) 2001-03-03 2002-03-01 Vaccine

Country Status (18)

Country Link
US (3) US20050260216A1 (enExample)
EP (1) EP1368477A1 (enExample)
JP (1) JP4238031B2 (enExample)
KR (1) KR20030081490A (enExample)
CN (1) CN1543504A (enExample)
AU (1) AU2002233560B2 (enExample)
BR (1) BR0207819A (enExample)
CA (1) CA2439628A1 (enExample)
CZ (1) CZ20032373A3 (enExample)
GB (1) GB0105360D0 (enExample)
HU (1) HUP0303372A3 (enExample)
IL (1) IL157498A0 (enExample)
MX (1) MXPA03007915A (enExample)
NO (1) NO20033882L (enExample)
NZ (1) NZ527873A (enExample)
PL (1) PL365066A1 (enExample)
WO (1) WO2002070711A1 (enExample)
ZA (1) ZA200306647B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001022972A2 (en) * 1999-09-25 2001-04-05 University Of Iowa Research Foundation Immunostimulatory nucleic acids
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
CA2496409A1 (en) * 2002-08-30 2004-03-11 Glaxo Group Limited Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use
JP2006501249A (ja) * 2002-08-30 2006-01-12 グラクソ　グループ　リミテッド ワクチン
WO2004024183A1 (en) * 2002-09-12 2004-03-25 Pharmexa A/S Immunization against autologous ghrelin
WO2004074432A2 (en) * 2003-01-31 2004-09-02 Celldex Therapeutics, Inc. Antibody vaccine conjugates and uses therefor
US9259459B2 (en) * 2003-01-31 2016-02-16 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
JP2007525436A (ja) * 2003-03-24 2007-09-06 マーシア・ファーマ・インコーポレイテッド 炎症症状を処置および予防するための方法および組成物
WO2004096849A2 (en) * 2003-04-25 2004-11-11 University Of Manitoba Peptide-based cytokine/chemokine vaccines against allergy
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
EP1767216B1 (en) 2004-06-11 2012-07-11 Riken Drug having regulatory cell ligand contained in liposome
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
EP2468300B1 (en) 2006-09-26 2017-12-20 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20090068195A1 (en) * 2007-04-23 2009-03-12 Wyeth Methods and compositions for treating and monitoring treatment of il-13-associated disorders
EP2155889A4 (en) * 2007-05-25 2010-06-16 Centocor Ortho Biotech Inc TOLL RECEPTOR 3 MODULATORS AND USES THEREOF
US8236318B2 (en) 2007-11-07 2012-08-07 Celldex Therapeutics Inc. Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
SMT201800368T1 (it) 2012-05-16 2018-09-13 Immune Design Corp Vaccini per l'infezione da virus-2 herpes simplex
CA2909221A1 (en) 2013-04-18 2014-10-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
AU2022215119A1 (en) * 2021-01-29 2023-08-17 Bayer Animal Health Gmbh Vaccine composition for breaking self-tolerance

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5278302A (en) * 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5697901A (en) * 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
AU661684B2 (en) * 1991-06-18 1995-08-03 Regents Of The University Of California, The Cloned glutamic acid decarboxylase
DE4137333A1 (de) * 1991-11-13 1993-05-19 W Prof Dr Sebald Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung
AU713040B2 (en) * 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
CZ25697A3 (en) * 1994-07-29 1997-09-17 Smithkline Beecham Plc Novel compounds
US5696234A (en) * 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13
EP0815136B1 (en) * 1995-02-20 2007-06-13 The Walter And Eliza Hall Institute Of Medical Research Immunoreactive and immunotherapeutic molecules which interact in subjects with insulin-dependent diabetes mellitus (iddm)
US5614191A (en) * 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US6518061B1 (en) * 1995-03-15 2003-02-11 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
EP0759468A1 (en) * 1995-08-10 1997-02-26 Laboratoires Virbac Feline interleukin-4
US5666153A (en) * 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US6664227B1 (en) * 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US5843449A (en) * 1996-03-25 1998-12-01 Akzo Nobel N.V. Proteins and novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases
US5856462A (en) * 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
ATE375363T1 (de) * 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
EP0911401A1 (en) * 1997-10-21 1999-04-28 Bayer Ag Muteins of interleukin 4 showing low-affinity and short-term interaction with the common gamma chain
AU758265B2 (en) * 1998-03-20 2003-03-20 Genzyme Corporation Induction of immunity against tumor self-antigens
US6576232B1 (en) * 1998-04-03 2003-06-10 The Penn State Research Foundation IL13 mutants
WO2000078334A1 (en) * 1999-06-17 2000-12-28 University Of Maryland Biotechnology Institute Chimeric chemokine-antigen polypeptides and uses therefor
WO2001034645A2 (en) * 1999-11-11 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Mutated il-13 molecules and their uses

Also Published As

Publication number Publication date
PL365066A1 (en) 2004-12-27
EP1368477A1 (en) 2003-12-10
NO20033882L (no) 2003-10-31
CZ20032373A3 (cs) 2004-01-14
US20050260216A1 (en) 2005-11-24
US20030194391A1 (en) 2003-10-16
HUP0303372A3 (en) 2008-06-30
NO20033882D0 (no) 2003-09-02
HUP0303372A2 (hu) 2004-01-28
KR20030081490A (ko) 2003-10-17
NZ527873A (en) 2005-12-23
IL157498A0 (en) 2004-03-28
JP2005502314A (ja) 2005-01-27
BR0207819A (pt) 2004-03-02
WO2002070711A1 (en) 2002-09-12
US20050186209A1 (en) 2005-08-25
CN1543504A (zh) 2004-11-03
ZA200306647B (en) 2004-11-26
GB0105360D0 (en) 2001-04-18
MXPA03007915A (es) 2003-12-04
JP4238031B2 (ja) 2009-03-11
CA2439628A1 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
US20050260216A1 (en) Vaccine
AU2002233560A1 (en) Vaccine
KR100671036B1 (ko) 오스테오프로테게린 리간드 활성을 하향-조절하는 방법
RU2248214C2 (ru) Слитые белки с fc-фрагментом иммуноглобулина для повышения иммуногенности белковых и пептидных антигенов
JP6987744B2 (ja) 虫刺され過敏症の治療
KR20020026544A (ko) Ｇｄｆ-8 활성을 하향-조절하는 방법
US6746669B1 (en) Method for down-regulating IL5 activity
US20060147417A1 (en) Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use
KR101101004B1 (ko) 신규한 펩티드 및 그들의 치료 용도
US20060104943A1 (en) Vaccine comprising il-13 and an adjuvant
EP1448598A2 (en) Novel immunogenic mimetics of multimer proteins
US20030185816A1 (en) Solubilised protein vaccines
CN101260152A (zh) 负调节Osteoprotegerin配体活性的方法
AU2002342596A1 (en) Immunogenic mimetics of multimer proteins with promiscuous T cell epitope inserts

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired